Alnylam Pharmace. buy StockNews.com
Start price
07.07.26
/
50%
€278.00
Target price
07.07.27
-
Performance (%)
-30.31%
Price
09:30
€193.75
Summary
This prediction is currently active. The BUY prediction by StockNews_com for Alnylam Pharmace. is performing very badly with a performance of -30.31%. This prediction currently runs until 07.07.27. The prediction end date can be changed by StockNews_com at any time. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 3.192% | 3.192% |
| iShares Core DAX® | -0.046% | 5.960% |
| iShares Nasdaq 100 | 0.922% | 3.693% |
| iShares Nikkei 225® | 3.014% | 6.638% |
| iShares S&P 500 | -0.359% | 2.747% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (ALNY) was downgraded by Wall Street Zen from "strong-buy" to "buy".
Ratings data for ALNY provided by MarketBeat